Radiation therapy firm Accuray achieved a 24% increase in worldwide use of its CyberKnife robotic radiosurgery system for prostate stereotactic body radiotherapy (SBRT) in its fourth quarter of fiscal 2011 (end-June 30) and 17% gain over the third fiscal quarter (end-March 31).
The CyberKnife system is designed as a noninvasive treatment option for prostate cancer to deliver targeted doses of radiation with enhanced accuracy to tumors while sparing surrounding healthy structures.
